Ballentine Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ballentine Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,987	Closed	-$340K	–	596
2022 Q4	$340K	Buy	+2,987	New	+$248K	0.01%	353
2017 Q4	–	Sell	-10,057	Closed	-$128K	–	450
2017 Q3	$128K	Sell	10,057 -200	-2%	-$2.54K	0.01%	375
2017 Q2	$139K	Buy	+10,257	New	+$128K	0.01%	365

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ballentine Partners's HZNP Position: Q1 2023 in Review

Ballentine Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 2,987 shares — an estimated $340K sold.

Ballentine Partners first reported a position in HZNP in Q2 2017 and held it in 3 quarters. The position peaked at $340K in Q4 2022. 552 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Ballentine Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Ballentine Partners sold 2,987 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $340K.
Ballentine Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017 and held it in 3 quarters.
Ballentine Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $340K in Q4 2022.
552 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Ballentine Partners's 13F filing for Q1 2023, filed 27 Apr 2023.